Combination Vaccine
Intervet introduces Continuum DAP, the first and only canine vaccine approved by the United States Department of Agriculture (USDA) for a three-year duration of immunity against distemper, adeno virus and parvovirus.
Intervet introduces Continuum DAP, the first and only canine vaccine approved by the United States Department of Agriculture (USDA) for a three-year duration of immunity against distemper, adeno virus and parvovirus.
Continuum DAP allows veterinarians to adhere to the American Animal Hospital Association triennial vaccination guidelines for core vaccines involving three serious and potentially deadly diseases, the company says.
Dr. Sebastian Huron, director of Intervet's Companion Animal Business Team, says of the introduction, "It's not all about a product; it's about a new concept in the way we vaccinate."
The vaccine contains attenuated strains of canine distemper virus, adenovirus type 2 and parvovirus.
Continuum DAP was evaluated based on the Code of Federal Regulations criteria for both serologic and real-time efficacy results.
"Veterinarians can feel confident that they are practicing the best medicine for dogs by providing 100-percent protection over three years," Huron says.
The product has been evaluated in dogs with challenge-of-immunity testing methodologies, which are considered the gold standard for evaluating vaccine efficacy.
To evaluate the efficacy of the vaccine, vaccinated dogs were compared with age-matched controls challenged three years following initial vaccination, the company says.
The product was released at the April AAHA meeting in Baltimore.
For fastest response, call
(800) 441-8272
